Zobrazeno 1 - 10 of 22 pro vyhledávání: '"Ioannis Kottakis"'
1
Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A Combination Therapy for Asthma
Autor: Alberto Papi, Konstantinos Kostikas, Ivan Nikolaev, Ioannis Kottakis
Publikováno v: Current Respiratory Medicine Reviews. 18:77-85
Abstract: Despite the wide range of available therapies, asthma remains uncontrolled in 40-65% of patients for a number of different reasons. Treatment with an inhaled corticosteroid (ICS) is rec-ommended in the Global Initiative for Asthma 2021 repo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25d3267578b73cc36048911b6ef14638
https://doi.org/10.2174/1573398x18666220217151845
Zobrazit plný text záznamu
2
Performance Characteristics of Breezhaler® and Aerolizer® in the Real-World Setting
Autor: Sonja Lederhilger, Mathieu Molimard, Juergen Jauernig, Ioannis Kottakis, Ivan Nikolaev
Publikováno v: Clinical Drug Investigation
Clinical Drug Investigation, Springer Verlag, 2021, ⟨10.1007/s40261-021-01021-w⟩
The evaluation of errors in use with different inhaler devices is challenging to quantify as there are a number of definitions of critical and non-critical errors with respect to inhaler use; in addition, performance characteristics of the device, su
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aba4e3d5720d9209cbb65758f609373
https://doi.org/10.1007/s40261-021-01021-w
Zobrazit plný text záznamu
4
IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy
Autor: Xavier Jaumont, Marc Humbert, Nikolaos G. Papadopoulos, Ioannis Kottakis, Oscar Palomares, Jean Bousquet, Simon Francis Thomsen, Pascal Pfister, Claus Bachert
Publikováno v: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
Journal of Allergy and Clinical Immunology: In Practice
Journal of Allergy and Clinical Immunology: In Practice, Elsevier, 2019, 7 (5), pp.1418-1429. ⟨10.1016/j.jaip.2019.02.030⟩
Humbert, M, Bousquet, J, Bachert, C, Palomares, O, Pfister, P, Kottakis, I, Jaumont, X, Thomsen, S F & Papadopoulos, N G 2019, ' IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy ', The Journal of Allergy and Clinical Immunology: In Practice, vol. 7, no. 5, pp. 1418-1429 . https://doi.org/10.1016/j.jaip.2019.02.030
Allergic asthma often coexists with different pathological conditions, called multimorbidities, that are mostly of allergic nature and share a common underlying inflammatory pathophysiological mechanism. Multimorbidities of allergic asthma may influe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::088a85952f1852928e2cad6050770165
https://doi.org/10.1016/j.jaip.2019.02.030
Zobrazit plný text záznamu
5
Performance Characteristics of Breezhaler
Autor: Mathieu, Molimard, Ioannis, Kottakis, Juergen, Jauernig, Sonja, Lederhilger, Ivan, Nikolaev
Publikováno v: Clinical Drug Investigation
The evaluation of errors in use with different inhaler devices is challenging to quantify as there are a number of definitions of critical and non-critical errors with respect to inhaler use; in addition, performance characteristics of the device, su
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::54d87b4793c17a7c98494153d0e22baa
https://pubmed.ncbi.nlm.nih.gov/33768480
Zobrazit plný text záznamu
6
Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and Caucasians
Autor: Xiangdongu Zho, Linda Wang, Xiaoxia Liu, Xixin Yan, Jing Li, Jing Yang, Ioannis Kottakis, Xiaoli Zhu, Jinming Liu, Lingfei Kong, Xinting Wang, Robert Fogel, Yijiang Huang, Michael Humphries, Nanshan Zhong, Abhijit Pethe, Ping Chen
Publikováno v: Asian Pacific journal of allergy and immunology. 40(3)
Background Omalizumab has > 15 years of real-world evidence of effectiveness in Caucasian patients. In August 2017, it was approved as an add-on therapy for the management of moderate-to-severe asthma in China. Objective To compare the efficacy and s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cff1f51fd6378c8f512678954077928c
https://pubmed.ncbi.nlm.nih.gov/32247304
Zobrazit plný text záznamu
7
Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson’s Disease
Autor: Thomas Müller, Gabriele Lazzeri, Ioannis Kottakis, Carlo Cattaneo, Charlotte Keywood, Erminio Bonizzoni
Publikováno v: Journal of Parkinson's Disease
Background Mood disorders are very frequent in Parkinson's Disease (PD), and their effective treatment is still a major unresolved issue: growing evidence suggests that glutamatergic system dysfunction is directly involved. Safinamide is a drug with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fee69b7aa640e1fb2f15a1a31171592
https://doi.org/10.3233/jpd-171143
Zobrazit plný text záznamu
8
Clinical consequences of late Chronic Obstructive Pulmonary Disease (COPD) diagnosis compared to early diagnosis in UK primary care
Autor: Bethan Jones, Konstantinos Kostikas, Emil Loefroth, Florian S. Gutzwiller, Ioannis Kottakis, Andreas Clemens, Hui Cao, Robert Fogel
Publikováno v: Airway pharmacology and treatment.
Background: Opportunities to diagnose COPD early are often missed in primary care. We examined the percentage of patients with early vs late diagnosis of COPD and investigated the clinical impact associated with late diagnosis compared to early diagn
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0c929b225f1265812aaac865ac9a20fa
https://doi.org/10.1183/13993003.congress-2019.pa2497
Zobrazit plný text záznamu
9
Health care resource utilization (HCRU) in early and late diagnosed Chronic Obstructive Pulmonary Disease (COPD) patients in UK primary care
Autor: Robert Fogel, Konstantinos Kostikas, Hui Cao, Bethan Jones, Ioannis Kottakis, Andreas Clemens, Florian S. Gutzwiller, Emil Leofroth
Publikováno v: Airway pharmacology and treatment.
Background: Previous studies have shown that opportunities to diagnose COPD at an early stage were missed in ~85% of patients. We investigated the HCRU between patients with early vs. late diagnosis of COPD. Methods: Newly diagnosed COPD patients wer
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a4b25f3c435662d36527f73e113f1b61
https://doi.org/10.1183/13993003.congress-2019.pa2496
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje